A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants
Clesrovimab was generally well tolerated and exhibited an extended half-life compared to typical IgG1 antibodies, supporting its ongoing development in late-stage trials. Clinical Trial Registration. NCT03524118.
Authors
- Armando Acevedo
- Brad Roadcap (ORCID: https://orcid.org/0000-0002-9292-0140)
- Antonios O. Aliprantis (ORCID: https://orcid.org/0000-0002-8744-2535)
- Xin Cao (ORCID: https://orcid.org/0000-0002-7633-845X)
- Radha Railkar
- Jose M Novoa Pizarro
- Xiaowei Zang (ORCID: https://orcid.org/0000-0002-8319-5303)
- Julie S. Shepard
- Kalpit A. Vora (ORCID: https://orcid.org/0000-0001-9844-634X)
- Andrea Likos Krick
- Andrew W. Lee
- Brian M. Maas (ORCID: https://orcid.org/0000-0002-2410-4379)
- Shabir Ahmed Madhi (ORCID: https://orcid.org/0000-0002-7629-0636)
- Eric A. F. Simões (ORCID: https://orcid.org/0000-0001-5588-2723)
- Anushua Sinha
Institutions
- South African Medical Research Council (ZA)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Colorado School of Public Health (US)
- University of the Witwatersrand (ZA)
- Children's Hospital Colorado (US)
- Dayton Clinical Oncology Program (US)
- Ohio Pediatric Research Association (US)
- Hospital Padre Hurtado (CL)
- Clinical Research Associates (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1093/infdis/jiae581
- Citations
- 34
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 13.15